Combigan is a fixed dose combination ophthalmic solution formulated to lower intraocular pressure in patients with glaucoma. The medication contains brimonidine tartrate, an alpha-2 adrenergic agonist, and timolol maleate, a non-selective beta-adrenergic antagonist. Brimonidine reduces the secretion of aqueous humor by stimulating alpha-2 receptors on ciliary epithelial cells, leading to decreased production of fluid. Timolol blocks beta-adrenergic receptors in the ciliary body, further limiting the synthesis and release of aqueous humor. The synergistic reduction in aqueous humor volume results in a measurable decline in intraocular pressure, which helps preserve optic nerve function. Together these actions provide dual pharmacologic control of ocular hypertension without altering outflow pathways.

Combigan is a prescription eye drop formulated to lower intraocular pressure in patients with glaucoma. The medication contains brimonidine tartrate and timolol maleate, two drugs that work through complementary mechanisms. Brimonidine is an alpha-2 adrenergic agonist that decreases the production of aqueous humor by acting on specific receptors in the eye. Timolol is a non-selective beta blocker that reduces aqueous humor secretion by blocking beta-adrenergic receptors in ocular tissue. Together, these actions increase the outflow of fluid from the eye and lower the pressure inside the eye. The combined effect results in a sustained reduction of intraocular pressure, which helps preserve visual function. Because the drug targets both production and drainage pathways, it provides a dual-approach therapy for glaucoma management.

The most common side effects reported across many medications include mild fatigue headache and occasional nausea. These effects often appear shortly after the first dose and may diminish as the body adjusts. Some individuals experience temporary dizziness which is usually brief and not severe. Digestive disturbances such as loose stools or mild abdominal discomfort are also frequently observed. In many cases skin reactions like mild redness or itching occur without causing alarm. Sleep disturbances including difficulty falling asleep or occasional vivid dreams can be noted during treatment. Most of these symptoms are mild and self limiting typically resolving without intervention. Monitoring personal response helps determine whether any effect persists or requires attention.

The most common side effects include mild fever and chills. Fatigue is often reported after vaccination and usually resolves within a few days. Headache and muscle aches are frequently observed and tend to be short lived. Some individuals experience soreness at the injection site without swelling or redness. Nausea and diarrhea can occur less commonly but are generally mild. These reactions are typically self limiting and do not require medical intervention.